Predictive implications of decreased CA19‐9 at 8 weeks during nab‐paclitaxel plus gemcitabine for the induction of second‐line chemotherapy for patients with advanced pancreatic cancer

BACKGROUND: Second‐line (2L) chemotherapy after nab‐paclitaxel plus gemcitabine (AG) is important for improving the survival of patients with advanced pancreatic cancer (APC). However, many patients fail to receive 2L chemotherapy because of rapid disease progression. Therefore, early recognition of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Rep (Hoboken)
Main Authors: Iede, Kiyotsugu, Yamada, Terumasa, Kato, Ryo, Ueda, Masami, Tsuda, Yujiro, Nakashima, Shinsuke, Ohta, Katsuya, Matsuyama, Jin, Ikenaga, Masakazu, Tominaga, Shusei
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7941508/
https://ncbi.nlm.nih.gov/pubmed/32969199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cnr2.1289
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados